Outcomes of treatment with daclatasvir and asunaprevir for recurrent hepatitis C after liver transplantation

Abstract

The DCV/ASV regimen was well tolerated, resulting in high rates of sustained viral response 12 weeks after completion of therapy for LT patients with recurrent HCV genotype 1 infection.

Direct‐acting antiviral agents for liver transplant recipients with recurrent genotype 1 hepatitis C virus infection: Systematic review and meta‐analysis

“…Except one study that did not report patient ethnicity, the majority of patients were Caucasian, male, with a mean age of approximately 60‐year‐old, had GT1a HCV recurrence, and received tacrolimus as part of their immunosuppressive treatment. Five different DAA combination protocols were described: SOF/SMV with or without RBV (n = 8); SOF/LDV (n = 3); ASV/SMV (n = 2); DCV/SMV with or without RBV (n = 2); PrOD (n = 1) . Detailed baseline characteristics of the included studies are provided in Tables and .…”

“…There is a trend that the first‐class of DAAs are commonly used in European or North American countries. For many countries, even like Japan, cost‐effectiveness other than SVR rate is the first consideration for clinicians . However, in Asia‐pacific or Africa countries, HCV has distinct epidemiology.…”

“…For many countries, even like Japan, cost-effectiveness other than SVR rate is the first consideration for clinicians. 24,25 However, in Asia-pacific or Africa countries, HCV has distinct epidemiology.…”

“…Five different DAA combination protocols were described: SOF/ SMV with or without RBV (n = 8) [13][14][15][16][17][18][19][20] ; SOF/LDV (n = 3) 21-23 ; ASV/ SMV (n = 2) 24,25 ; DCV/SMV with or without RBV (n = 2) 26,27 ; PrOD (n = 1). 28 Detailed baseline characteristics of the included studies are provided in Tables 1 and 2.…”